#Asia Pacific Inflammatory Bowel Disease Treatment Market | Explore Tumblr posts and blogs

abhilashnale · 1 month ago

Text

Inflammatory Bowel Disease Treatment Market Global Demand Analysis: Sales Consumption, Business Scenario, and Expert Reviews, Forecast by 2032

The Market Dynamics of the Inflammatory Bowel Disease Treatment

The global Inflammatory Bowel Disease Treatment market has emerged as a critical focal point for businesses, offering a wealth of opportunities and challenges. As industries navigate this complex landscape, understanding the underlying market dynamics becomes crucial for strategic decision-making and growth.

According to Straits Research, the global inflammatory bowel disease treatment market size was valued at USD 20.33 Billion in 2022. It is projected to reach from USD XX Billion in 2023 to USD 27.95 Billion by 2031, growing at a CAGR of 3.6% during the forecast period (2023–2031).

Historically, the Inflammatory Bowel Disease Treatment market has witnessed significant transformations, driven by technological innovations, regulatory changes, and evolving consumer preferences. These shifts have reshaped the market landscape, presenting businesses with new avenues for growth, innovation, and competitiveness.

Note: Our reports are currently under revision. To access the most recent primary and secondary data spanning 2023-2031, inclusive of Cost Module, Business Strategy, and Competitive Landscape insights, please click on ""request free sample report."" Expect the report in your inbox within 24 to 48 hours.

Get Access to a Free Copy of Our Latest Sample Report@https://straitsresearch.com/report/inflammatory-bowel-disease-treatment-market/request-sample

Companies and Manufacturers Covered:

Key market players play a pivotal role in shaping the market narrative. By profiling industry leaders, their strategic initiatives, and competitive positioning, the report offers insights into market dynamics, influencing factors, and growth opportunities. These insights are invaluable for businesses seeking to gain a competitive edge, drive innovation, and capitalize on emerging trends.

AbbVie Inc.

Takeda Pharmaceutical Company Limited

Pfizer Inc

Biogen

Novartis AG, Lilly

UCB S.A.

CELLTRION INC.

Merck & Co., Inc

Johnson & Johnson Services, Inc.

The quantitative analysis accompanying the report offers a decade-long perspective on the market's trajectory. By examining historical data, identifying trends, and forecasting future developments, stakeholders can gain a deeper understanding of market dynamics and make informed decisions.

Buy this Premium Research Report@https://straitsresearch.com/buy-now/inflammatory-bowel-disease-treatment-market

A recent comprehensive analysis provides a detailed overview of the Global Inflammatory Bowel Disease Treatment Market, highlighting key growth drivers, emerging trends, and market dynamics. This report serves as an invaluable resource for businesses, offering insights into the market landscape, competitive positioning, and growth prospects.

Global Regional Outlook:

North America: North America is currently the largest market for Inflammatory Bowel Disease Treatment, accounting for a significant share of the global market.

Asia-Pacific: While the North America leads in market size, Asia-Pacific is emerging as the fastest growing region in the Inflammatory Bowel Disease Treatment market.

Research Methodology

The research methodology employed in curating this report is rigorous and comprehensive. By leveraging both primary and secondary data sources, the report ensures accuracy, reliability, and depth. Through interviews with industry experts, analysis of Inflammatory Bowel Disease Treatment market trends, and examination of key growth drivers, the report offers a holistic view of the market landscape.

Market Segmentation:

By Type

Crohn’s Disease

Ulcerative Colitis

By Drug Class

Aminosalicylates

Corticosteroids

TNF inhibitors

IL inhibitors

Anti-integrin

JAK inhibitors

Others

By Route of Administration

Injectable

Oral

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Ask Here For More Customization Study@https://straitsresearch.com/report/inflammatory-bowel-disease-treatment-market/toc

Report Features:

Actionable market intelligence for strategic decision-making

Comprehensive forecasts spanning 2018to 2031

In-depth growth trend assessments

Segment-specific and regional revenue projections

Competitive analysis and market share insights

Innovative product listings for competitive advantage

Insights into the market implications of COVID-19

Report availability in various formats: PDF, XLS, PPT, and digital dashboards

In conclusion, the global Inflammatory Bowel Disease Treatment market presents a dynamic and evolving landscape for businesses. By understanding market dynamics, leveraging strategic insights, and adopting a proactive approach, businesses can navigate this complex landscape successfully, drive growth, and achieve sustainable success.

Report Customization:

Our report is adaptable to your specific needs. For tailored insights, please reach out to our sales team at [email protected]. Additionally, you can contact our representatives directly at +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.) to discuss your research criteria.

0 notes

tumbrl1 · 7 days ago

Text

Butyric Acid Market Potential: Emerging Trends and Applications

Butyric acid, a short-chain fatty acid, is emerging as a significant compound across various industries, driven by its versatile applications in food, pharmaceuticals, agriculture, and chemicals. With growing consumer awareness about health and wellness, and the increasing need for sustainable solutions, the potential for butyric acid in the market is vast. In this article, we explore the untapped opportunities in the butyric acid market and analyze the factors contributing to its rapid growth.

Key Market Drivers

Several factors are driving the growing demand for butyric acid across diverse sectors:

Rising Demand in Animal Feed: Butyric acid has proven benefits as a gut health promoter in livestock, particularly in poultry, swine, and cattle. By enhancing nutrient absorption and improving gut flora, butyric acid helps reduce the use of antibiotics in animal feed, aligning with growing trends for sustainable and healthier agricultural practices. As global meat consumption rises, the demand for butyric acid in animal feed is expected to surge.

Growth of the Functional Food Market: Butyric acid plays a vital role in promoting digestive health by supporting gut microbiota. The increasing focus on preventive healthcare and gut health has led to a surge in demand for functional foods that contain butyric acid. This trend is contributing significantly to the market’s potential, especially as more consumers embrace a health-conscious lifestyle. Butyric acid is increasingly being used in dietary supplements targeting digestive issues and overall wellness.

Pharmaceutical Applications: Butyric acid is gaining attention in the pharmaceutical sector due to its anti-inflammatory properties and potential therapeutic applications. It has shown promise in the treatment of chronic gastrointestinal conditions such as Inflammatory Bowel Disease (IBD), irritable bowel syndrome (IBS), and other inflammatory disorders. Research into its potential as a treatment for metabolic diseases and cancer is opening up new opportunities for butyric acid in the pharmaceutical market.

Technological Advancements: Innovations in biotechnology, particularly fermentation technology, are improving the efficiency and scalability of butyric acid production. These advances are reducing production costs, making butyric acid more affordable and accessible. As the process becomes more cost-effective, demand is likely to rise in various applications, from food to pharmaceuticals.

Emerging Applications and Innovations

As new research uncovers the benefits of butyric acid, more applications are emerging across multiple industries. In the food sector, butyric acid is increasingly being used as a flavoring agent, contributing to the distinctive flavor of dairy products like cheese and butter. Additionally, it’s being explored as a preservative in processed foods, providing an alternative to artificial additives.

Butyric acid is also being studied for its potential use in the cosmetic and personal care industries. Research is ongoing into its role in skin health, as it has shown potential as a natural anti-inflammatory agent in skincare formulations.

Moreover, in agriculture, the demand for more eco-friendly and sustainable practices is driving the use of butyric acid as a feed additive that promotes better animal health while reducing the environmental impact of livestock farming.

Geographic Market Potential

Geographically, the butyric acid market has strong growth potential in emerging economies, particularly in Asia-Pacific, Latin America, and Africa. In these regions, the expanding agricultural industry, coupled with the rising consumption of processed foods, presents a significant opportunity for butyric acid producers. The rising middle class, urbanization, and increasing awareness about health are expected to drive the demand for functional foods, dietary supplements, and animal feed, which are the primary drivers of butyric acid consumption.

North America and Europe remain the largest markets for butyric acid, driven by established industries in pharmaceuticals, food, and agriculture. However, the rapid growth in health-consciousness and demand for organic and sustainable products in emerging markets presents untapped potential for market expansion.

Challenges and Market Constraints

Despite the promising potential, the butyric acid market faces challenges that may hinder its growth. High production costs, particularly in fermentation-based methods, remain a major constraint. While technological advancements are helping reduce costs, the commercial-scale production of butyric acid still requires significant investment.

Additionally, regulatory hurdles in various regions could delay the widespread use of butyric acid in food and pharmaceutical products. Companies will need to navigate complex regulatory landscapes to ensure that products meet safety and quality standards.

Conclusion

The butyric acid market is poised for significant growth due to its expanding applications in animal feed, food, pharmaceuticals, and agriculture. With increasing consumer demand for health-focused products, innovations in production technology, and the growing emphasis on sustainable practices, the potential for butyric acid in the market is immense. Companies that invest in research and development, explore new applications, and improve production efficiency are well-positioned to capitalize on the growing demand for this versatile compound.

Get Free Sample and ToC : https://www.pristinemarketinsights.com/get-free-sample-and-toc?rprtdtid=NDcy&RD=Butyric-Acid-Market-Report

0 notes

adityarana1687-blog · 2 months ago

Text

On-body Injectors Market Size To Reach $12.7 Billion By 2030

The global on-body injectors market size is expected to reach USD 12.7 billion by 2030, registering a CAGR of 14.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The on-body injectors increase patient adherence to medication by offering easy-to-use, less pain and enabling extended drug administration without frequent hospital visits. These advantages of on-body injectors are significantly increasing their popularity. Moreover, regions such as Asia Pacific, with developing healthcare infrastructure and rising adoption of advanced medical devices, offer huge opportunities for market growth over the forecast period.

The increasing concerns over needle stick injuries and the need to increase the safety for both patients and healthcare professionals by eliminating risks associated with needle insertion, drug preparation, and covering & disposing of needles, coupled with the increasing prevalence of chronic diseases such as cancer are some of the factors expected to drive the market growth over the forecast period.

According to the WHO agency International Agency for Research on Cancer (IARC), around 20 million people were diagnosed with cancer, and around 9.7 million mortalities occurred due to cancer in 2022. Several cancers and other chronic disease treatments require frequent injections of medications over extended periods. On-body injectors offer a convenient and potentially less disruptive alternative for patients to receive these medications compared to traditional hospital visits or self-administered injections, which can significantly increase their demand over the forecast period.

Request a free sample copy or view report summary: On-body Injectors Market Report

On-body Injectors Market Report Highlights

Based on the technology, the spring-based segment accounted for the largest revenue share of 40.89% in 2023 owing to their consistent pressure and speed, which ensures precise dosing

Based on technology, the rotary pump segment is expected to grow at the fastest CAGR of 15.1% during the forecast period owing to the high control offered by them in dispensing medications, minimizing the risk of dosing errors and maximizing therapeutic efficacy

Based on the application, the diabetes segment accounted for the largest revenue share in 2023 due to the high prevalence of type 2 diabetes, which requires frequent administration

Based on the application, the autoimmune diseases segment is expected to grow at the fastest CAGR owing to the rising prevalence of chronic autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and Inflammatory Bowel Diseases (IBD)

Based on the end use, the homecare segment accounted for the largest revenue share in 2023 owing to the growing preference for self-administration of medications for managing chronic conditions such as diabetes, autoimmune disorders, and cancer in homecare settings

In 2023, North America dominated with a share of 33.17%, driven by the presence of key market players, an increasing shift toward home care, and better access to advanced on-body injectors

On-body Injectors Market Segmentation

Grand View Research has segmented the global on-body injectors market based on technology, application, end-use, and region:

On-body Injectors Technology Outlook (Revenue, USD Million, 2018 - 2030)

Spring-based

Motor-driven

Rotary Pump

Expanding Battery

Other

On-body Injectors Application Outlook (Revenue, USD Million, 2018 - 2030)

Oncology

Diabetes

Cardiovascular Disease

Autoimmune Disease

Others

On-body Injectors End Use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals & Clinics

Home Care Settings

Others

On-body Injectors Region Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players in the On-body Injectors Market

West Pharmaceutical Services, Inc.

Stevanato Group

Enable Injections

Nemera

Debiotech SA

AbbVie, Inc.

Coherus BioSciences, Inc.

Gerresheimer AG

E3D Elcam Drug Delivery Devices

#On-body Injectors Market

0 notes

colinwilson11 · 3 months ago

Text

Necrotising Enterocolitis Market Will Grow At Highest Pace Owing To Rising Prevalence Of Preterm Birth Complications

Necrotising enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. It is characterized by inflammation and necrosis of the intestine. The risk factors associated with NEC include prematurity, formula feeding, and bacterial colonization of the intestine. Infants with very low birth weights have the highest risk. NEC treatment involves management of sepsis, support of vital organ function, bowel rest with no oral feeding, and surgery if necessary.

The Necrotising Enterocolitis Market is estimated to be valued at US$ 7.10 Bn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the Necrotising Enterocolitis market are AbbVie, AstraZeneca, Baxter International, Bristol-Myers Squibb, Fresenius Kabi. Rising prevalence of preterm birth complications globally is expected to drive the growth of the market during the forecast period. According to the World Health Organization, preterm birth complications are the leading cause of death among children under 5 years of age, responsible for approximately 1 million deaths in 2015. Technological advancements in parenteral nutrition and minimal invasive surgery have provided improved treatment outcomes for NEC.

Market Trends

Increasing research on nutraceuticals and probiotics for NEC prevention: Several clinical studies are evaluating the role of pre and probiotics such as Lactobacillus and Bifidobacterium in reducing the risk of NEC in preterm infants. This presents an opportunity for novel prevention strategies.

Rising adoption of minimal invasive surgery: Advancements in minimal invasive surgical techniques such as laparoscopy has resulted in reduced recovery time and complications for NEC patients undergoing surgery. This trend is expected to drive the future demand.

Market Opportunities

Development of novel therapeutics targeting inflammatory pathways: Researchers are investigating potential drug targets such as Toll-like receptor 4 (TLR4) and nuclear factor kappa B (NF-κB) signaling pathways to develop novel anti-inflammatory therapies for NEC treatment.

Increasing healthcare expenditure on pediatric care in emerging nations: Emerging countries in Asia Pacific and Latin America are witnessing increased healthcare spending focused on neonatal and pediatric care. This will propel the growth of therapeutics and medical devices market for pediatric gastrointestinal conditions.

Impact Of COVID-19 On Necrotising Enterocolitis Market Growth

The COVID-19 pandemic has adversely impacted the growth of the necrotising enterocolitis market globally. During the peak of pandemic in 2020-2021, the concentration of healthcare resources towards treatment of COVID-19 patients has negatively affected the diagnosis and treatment of other health conditions including necrotising enterocolitis. This led to reduction in number of surgeries and procedures carried out for necrotising enterocolitis management. Moreover, restrictions on non-essential healthcare services along with fear of virus spread stopped patients from visiting hospitals even for emergency cases. This impacted the market growth negatively during the period.

However, with gradual lift of restrictions in 2022 and availability of COVID-19 vaccines, the market is recovering slowly. The healthcare facilities are focusing on clearing backlog of non-COVID cases and regaining lost momentum in treatment of other diseases. The manufacturers are expanding supply chain capabilities and ramping up production to meet the increasing demand. Various initiatives are being taken by governments and healthcare organizations to raise awareness about timely management of necrotising enterocolitis. This will potentially boost the market in the coming years.

The United States holds the major share of necrotising enterocolitis market in terms of value, owing to large patient population, high treatment cost and adequate reimbursement framework. The region accounted for over 35% revenue share of global market in 2024.

Asia Pacific region is poised to witness fastest growth during the forecast period. Factors such as increasing healthcare expenditure, rising medical tourism, growing birth rate and expanding private hospital infrastructure will aid the market growth in Asia Pacific. China, India and Japan are emerging as profitable markets for necrotising enterocolitis treatment.

Get more insights on this topic: https://www.trendingwebwire.com/necrotising-enterocolitis-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-parenteral-nutrition-solutions-and-devices/

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

What Are The Key Data Covered In This Necrotising Enterocolitis Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Necrotising Enterocolitis Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Necrotising Enterocolitis Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Necrotising Enterocolitis Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Necrotising Enterocolitis Market vendors

FAQ’s

Q.1 What are the main factors influencing the Necrotising Enterocolitis Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Necrotising Enterocolitis Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Necrotising Enterocolitis Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

#Necrotising Enterocolitis Market Trend #Necrotising Enterocolitis Market Size #Necrotising Enterocolitis Market Information #Necrotising Enterocolitis Market Analysis #Necrotising Enterocolitis Market Demand

0 notes

businessindustry · 3 months ago

Text

Primary Sclerosing Cholangitis Market Size, Share and Future News by 2032

The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market Trends share, size, growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Primary Sclerosing Cholangitis Market?

The global primary sclerosing cholangitis market was valued at US$ 162.3 Million in 2023 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 319.1 Mn in 2032.

What are Primary Sclerosing Cholangitis?

Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389

What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?

The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Type

Classic PSC

Variant PSC

PSC Associated with Autoimmune Hepatitis

PSC with Cholangiocarcinoma

By Treatment Type

Ursodeoxycholic Acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Route of Administration

Oral

Parental

Others

By End-User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Acorda Therapeutics, Inc.

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Falk Pharma GmbH

Allergan Plc.

Shire Plc.

Durect Corporation

Conatus Pharmaceuticals, Inc.

Sirnaomics, Inc.

Shenzhen HighTide Biopharmaceutical Ltd.

Cymabay Therapeutics

Pliant Therapeutics

Immunic AG

View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

#Primary Sclerosing Cholangitis Market share #Primary Sclerosing Cholangitis Market size #Primary Sclerosing Cholangitis Market trends

0 notes

organicbusinessconsulting · 8 months ago

Text

Asia Endoscopy Medical Device Market Size, Share & Demand 2032

The Asia Endoscopy Medical Device Market is estimated to reach USD XX billion by 2032 with a CAGR of XX%.

The Asia Endoscopy Medical Device market has experienced significant growth and development in recent years. Endoscopy is a minimally invasive diagnostic and therapeutic procedure that allows physicians to examine the internal organs of the body using an endoscope. The market in Asia is primarily driven by factors such as the rising prevalence of gastrointestinal disorders, increasing geriatric population, technological advancements in endoscopic devices, and growing awareness about the benefits of minimally invasive procedures.

Countries like China, Japan, India, and South Korea are major contributors to the market growth in the region. These countries have well-established healthcare infrastructure, increasing healthcare expenditure, and a high demand for advanced medical devices. Additionally, the presence of key market players, such as Olympus Corporation, Fujifilm Holdings Corporation, and Boston Scientific Corporation, further fuels market growth through continuous product innovation and strategic collaborations. However, the market also faces challenges such as the high cost of endoscopic procedures and the lack of skilled professionals.

Get Full Analysis Report: https://organicmarketresearch.com/asia-endoscopy-medical-device-market

Exploring the Growth Drivers of the Asia Endoscopy Medical Device Industry

The Asia Endoscopy Medical Device market is driven by several growth factors that contribute to its expansion and development. Firstly, there is a growing prevalence of gastrointestinal disorders in the region, such as gastrointestinal cancers, inflammatory bowel diseases, and gastrointestinal bleeding. These conditions require accurate diagnosis and effective treatment, which can be facilitated by endoscopic procedures.

Secondly, the Asia-Pacific region has a significant geriatric population, which is prone to various age-related medical conditions. Endoscopy offers a minimally invasive approach for diagnosing and treating these conditions in elderly patients, leading to increased demand for endoscopic devices.

Technological advancements in endoscopic devices also play a crucial role in driving market growth. Innovations such as high-definition imaging, flexible endoscopes, and robotic-assisted endoscopy enhance the accuracy and efficiency of procedures, attracting healthcare providers and driving market demand.

Moreover, the increasing awareness among patients and healthcare professionals about the benefits of minimally invasive procedures is fueling the adoption of endoscopy in the region. Compared

What challenges does the Asia Endoscopy Medical Device Market face?

The Asia Endoscopy Medical Device market faces several challenges that can impact its growth and development. Firstly, the high cost of endoscopic procedures and devices is a significant challenge, particularly in emerging economies. The expenses associated with equipment, maintenance, and training can limit the accessibility of endoscopy to a larger population.

Secondly, there is a shortage of skilled healthcare professionals trained in performing endoscopic procedures. The complex nature of these procedures requires specialized training, and the limited number of experts can result in delays and inadequate access to endoscopic services.

Additionally, regulatory hurdles and lengthy approval processes for new endoscopic devices can hinder market growth. Obtaining regulatory clearances and complying with diverse regulatory frameworks across different countries in the region can be time-consuming and costly for manufacturers.

Moreover, the lack of awareness among patients and healthcare professionals about the benefits of endoscopy and its potential applications can pose a challenge. Educating both the medical community and the general public about the advantages and effectiveness of endoscopic procedures is crucial for increasing acceptance and demand.

In what ways has the COVID-19 pandemic affected Asia Endoscopy Medical Device Market?

The COVID-19 pandemic has had a significant impact on the Asia Endoscopy Medical Device market. Firstly, the postponement or cancellation of non-urgent medical procedures during the pandemic led to a decline in the number of endoscopic procedures performed. Many hospitals and healthcare facilities were focused on treating COVID-19 patients, resulting in a reduced demand for endoscopy devices.

Secondly, supply chain disruptions caused by the pandemic affected the manufacturing and distribution of endoscopy medical devices. Restrictions on international trade, temporary factory closures, and transportation challenges resulted in delays and shortages of essential components and equipment.

Furthermore, there were limitations in healthcare resources and personnel due to the overwhelming demand for COVID-19 care. The diversion of resources and staff to manage the pandemic created challenges in maintaining regular endoscopy services, leading to reduced access and longer waiting times for patients.

Additionally, concerns about infection control and the risk of virus transmission during endoscopic procedures led to increased safety protocols and precautions. These measures, such as the use of personal protective equipment (PPE) and enhanced disinfection practices, increased the overall cost and complexity of conducting endoscopy procedures.

Key Target Audience

Medical Device Manufacturers

Hospitals and Clinics

Healthcare Professionals (Surgeons, Physicians)

Distributors and Suppliers

Regulatory Authorities and Compliance Agencies

Research and Development Institutions

Asia Endoscopy Medical Device Market Segmentation

1. Product Type

Endoscopes

Visualization Systems

Endoscopic Ultrasound Systems

Endoscopic Accessories

2. Application

Gastrointestinal Endoscopy

Laparoscopy

Bronchoscopy

Arthroscopy

Urology Endoscopy

Gynecology Endoscopy

Others

3. End User

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Specialty Clinics

Others

4. Price Range

Premium-Priced Devices

Mid-Priced Devices

Economy-Priced Devices

5. By Country

China

Japan

India

South Korea

Australia

Contact Us: Mob : +91 9319642100 Noida One Tower Sec 62 Noida 201301 Sales : [email protected] Website : https://www.organicmarketresearch.com

#Endoscopy Medical Device Market #medical devices

0 notes

blog-site-for-market-research · 9 months ago

Text

Emerging Trends and Opportunities in the Ulcerative Colitis Market

Market Overview –

The size of the ulcerative colitis market was estimated at USD 7.2 billion in 2022 and is expected to increase at a compound annual growth rate (CAGR) of 5.1% between 2023 and 2032, from USD 7.5744 billion in 2023 to USD 10.77 billion.

The Ulcerative Colitis (UC) market pertains to a chronic inflammatory bowel disease characterized by inflammation and ulceration of the colon and rectum. UC significantly impacts patients' quality of life, causing symptoms such as abdominal pain, diarrhea, rectal bleeding, and fatigue. The market offers various treatment options, including aminosalicylates, corticosteroids, immunomodulators, biologics, and surgical interventions, aimed at inducing and maintaining remission and preventing disease complications.

The ulcerative colitis market is experiencing significant growth as awareness of this chronic inflammatory bowel disease increases. With a focus on developing effective treatments to manage symptoms and induce remission, pharmaceutical companies are actively investing in research and development. The market for ulcerative colitis disease management continues to expand, offering hope to patients worldwide.

With the rising incidence and prevalence of UC globally, there's a growing demand for innovative therapies that offer improved efficacy, safety, and convenience. Biologic agents targeting specific inflammatory pathways have emerged as a mainstay of treatment for moderate to severe UC, revolutionizing disease management and providing new hope for patients who are refractory to conventional therapies. Additionally, ongoing research efforts focused on understanding the underlying pathogenesis of UC and identifying novel therapeutic targets are driving innovation in the market. As a result, the UC market is poised for continued growth, offering better treatment options and improved outcomes for patients living with this debilitating condition.

Segmentation –

Global Ulcerative Colitis Market is segmented on the basis of types and medication. Based on types, the market is segmented as ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Ulcerative proctitis is expected to command the largest market share during the forecast period. Further on the basis of medication the market is classified into 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics. Biologics are expected to command the largest market. Steroids drugs are expected to grow at the highest CAGR during the forecast period.

Regional Analysis –

The ulcerative colitis (UC) market's regional dynamics are shaped by factors like disease prevalence, access to healthcare, and treatment options. In developed regions like North America and Europe, high prevalence rates and advanced healthcare infrastructure drive market growth for UC treatments. Biologic therapies and immunosuppressants are widely available, leading to better disease management outcomes. In contrast, regions such as Asia-Pacific, Latin America, and Africa face challenges in UC management due to limited access to specialty care and higher treatment costs. However, increasing awareness of UC and government initiatives to improve healthcare access are driving market growth in these regions. Market players must adapt their strategies to address regional disparities by offering affordable treatment options, supporting patient education initiatives, and collaborating with local healthcare providers to improve UC management globally.

Key Players –

Ulcerative Colitis companies include Salix Pharmaceuticals, Abbott Laboratories, Mitsubishi Tanabe Pharma Corporation, Celgene Corporation, InDex Pharmaceuticals Holding AB, BioLineRx Ltd, Sanofi Aventis A/S, Merck & Co, Eli Lilly, and Johnson & Johnson.

Related Reports –

Protein Engineering Market Research Report - Forecast Till 2032

Dental Carpule Market Research Report - Forecast Till 2030

North American Dental Software Market Research Report - Forecast to 2030

upper GI series market research report - Forecast till 2030

For more information visit at MarketResearchFuture

#Ulcerative Colitis Market #MRFR

0 notes

pavanpj · 1 year ago

Text

"Ulcerative Colitis Therapeutics Market Analysis: Size, Share, and Emerging Trends"

The global ulcerative colitis therapeutics market is anticipated to rise at a CAGR of 5.1% from 2021 to 2027. In 2020, revenue from ulcerative colitis therapeutics was US$ 5.6 Bn, which is expected to reach US$ 7.9 Bn by 2027.

The offer in this portion accompanies many open doors including fabricating items, appropriation, retail, and showcasing administrations. Broad rounds of essential and far reaching optional exploration have been utilized by the examiners at Fact.MR to show up at different assessments and projections for Demand of Ulcerative Colitis Therapeutics Market both at worldwide and provincial levels.

Download a Sample Copy of This Report: –https://www.factmr.com/connectus/sample?flag=S&rep_id=7286?PJ

Market Players: –

Abbott Laboratories, Inc.

AstraZeneca PLC

Avaxia Biologics, Inc.

BioLineRx Ltd.

Astellas Pharma, Inc.

Cosmo Pharmaceuticals NV

AbbVie, Inc.

Amgen, Inc.

Competitive Landscape

The market for ulcerative colitis therapeutics is highly competitive. Certain strategic efforts, such as mergers, new product launches, acquisitions, and collaborations, are implemented by key players to help them increase their market position.

For instance :

In May 2021, The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of individuals with moderately to highly active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).

What Do You Get in a Fact.MR Study?

Factors affecting the overall development of the global Ulcerative Colitis Therapeutics Market

Factor that might restrain the growth of the global market in the coming years of the forecast period.

What is present competitive scenario of the global Ulcerative Colitis Therapeutics Market and its intricate details concerning potential business prospects of leading market players

Pricing strategies of several different market players in the global Ulcerative Colitis Therapeutics Market

Regional analysis includes

North America (U.S., Canada)

Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM)

EU — (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe

CIS & Russia

Japan

Asia Pacific Excluding Japan (Greater China, India, S. Korea, ASEAN Countries, Rest of APEJ)

“Innovative Therapeutics for Ulcerative Proctitis Driving Market Revenue”

The ulcerative proctitis segment is projected to record a 4.7% CAGR and reach US$ 2.1 Bn over the forecast period. One of the types of ulcerative colitis is ulcerative proctitis. Fine ulcerations in the inner linings of the large intestine mucosa are visible, and it is thought to be the first sign of ulcerative proctitis.

The segment is expected to grow due to increased research & development initiatives in the discovery of innovative therapeutics for ulcerative proctitis. Market revenue is being boosted by a growth in the number of inflammatory bowel diseases, ulcerative proctitis diseases, and the development of new ulcerative proctitis medications in clinical laboratories.

0 notes

healthcareanna · 1 year ago

Text

Autoimmune Disease Treatment Market Report Insights, Global Strategies & Growth Factors

Autoimmune Disease Treatment Market Overview

Market Research Future (MRFR)’s latest assessment reveals that the global autoimmune disease treatment market share is expected to thrive at Steady CAGR during the forecast period. The market signifies massive unmet needs for diagnosis. It is projected to favor the expansion of the global market by bringing advanced, precise and effective drugs and treatments.

Definite causes for the development of autoimmune diseases have not been identified. Thus, the emphasis is on the early diagnosis of the disease. Increasing awareness coupled with large-scale prevalence is likely to aid the proliferation of the Autoimmune Disease Treatment Market Overview in the foreseeable future.

Expenditures for the treatment of these diseases are on the rise and is poised to exhibit a similar trend in the forthcoming years. As per the National Institutes of Health (NIH), the U.S., the healthcare expenditure for autoimmune diseases has reached half of that of the cancer expenditure. Furthermore, the introduction of favorable policies for insurance reimbursements are anticipated to augment the market over the next couple of years. However, factors such as side effects, counterfeit drugs, and expensiveness of the treatment are forecasted to check the expansion of the autoimmune disease treatment market across the review period.

Competitive Dashboard:

Autoimmune Disease Treatment MarketPlayers are Abbott Laboratories, Genentech Inc., Bayer Schering Pharma AG, Amgen Inc., Biogen Idec Inc., Chugai Pharmaceutical Co. Ltd., Danaher, Bio-Rad, Elan Corporation Plc, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Eli Lilly and Company, Johnson & Johnson Inc., Siemens, Squibb Company, Merck & Co. Inc., and Thermo Fisher Scientific.

Market Segmentation

By disease type, the global autoimmune disease treatment market has been segmented into localized, and systemic. The localized segment is further sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.

By diagnosis, the autoimmune disease treatment market outlook has been segmented into ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.

By therapeutic products, the market has been segmented into drugs and therapeutic and monitoring equipment. The drugs segment is further sub-segmented into biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.

By distribution channel, the autoimmune disease treatment market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis

The autoimmune disease treatment market report spans across Asia Pacific, Americas, Europe, and the Middle East & Africa. Americas signifies a huge potential for growth owing to increasing patient population. In addition, the increase witnessed in the expenditures associated with medical facilities is prognosticated to favor the expansion of the market over the next couple of years. The region has been estimated to gain control over the largest share of market in the forthcoming years.

The government of Europe has extended firm support in favor of research & development in the healthcare sector. This, in turn, is likely to pave the way for the growth of the in the region. It is expected to place the region on the second spot globally over 2023.

Asia Pacific has unleashed immense opportunities in the market through rapid developments witnessed in the healthcare sector. The population has also created a positive influence on the growth of the market by increasing its healthcare expenditures.

Related reports-

Heart Transplant Market Research Report - Global Forecast till 2030

Bladder Cancer Market Research Report - Forecast to 2030

CBD Hemp Oil Market Research Report â€“ Forecast to 2030

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

#Medical Devices #Health #Science #Medical #Healthcare #Autoimmune Disease Treatment Market #Autoimmune Disease Treatment Market Share #Autoimmune Disease Treatment Market Size

0 notes

delvens-blog · 1 year ago

Text

Medical Cannabis Market at a Highest CAGR of 22.12% by 2030

Medical Cannabis Market, by Product (Oil, Medical Cannabis Capsules, Patch, Whole Flower, Ground Flower, Vape Pen, Dried Medical Cannabis, Creams & Moisturizer, Masks & Serum, Cleanser, and Others), Source (Natural and Synthetic), Species (Cannabis Indica, Sativa, and Hybrid), Application (Alzheimer’s Disease, Appetite Loss, Cancer, Inflammatory Bowel Diseases, Eating Disorders, Epilepsy, Autism, Mental Health Conditions, Multiple Sclerosis, Pain Management, Nausea, Muscle Spasms, Wasting Syndrome (Cachexia), Elevate Mood, Depression and Sleep Disorders, Anxiety, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Request Sample Pages of Report: https://www.delvens.com/get-free-sample/medical-cannabis-market-trends-forecast-till-2030

Market Overview

The Medical Cannabis market size was estimated at USD 16.85 billion in 2023 and is projected to reach USD 68.26 billion in 2030 at a CAGR of 22.12% during the forecast period 2023-2030.

Medical Cannabis refers to the use of the cannabis plant of its derivatives, such as cannabinoids like THC and CBD, for medical purposes. It is used to treat various conditions, like chronic pain, epilepsy, multiple sclerosis, and nausea associated with chemotherapy and many more. Its legality and availability vary by country and region. The two main active compounds in cannabis are tetrahydrocannabinol (THC) and cannabidiol (CBD), each of which has distinct effects on the body.

Medical cannabis can be administered through various methods such as smoking, vaping, edibles, oil and tinctures, topicals, capsules, etc. However, it is important to note that while medical cannabis holds potential benefits, its not without risks. Side effects can include dizziness, dry mouth, impaired cognitive function, and in some cases, increased anxiety or paranoia. Additionally, its legality and regulations vary widely around the world, with some places allowing medical use under strict conditions and others not permitting it at all.

The medical cannabis market is expected to grow significantly in the forecast period driven by factors such as the increasing legalization of medical cannabis in various countries, rising prevalence of chronic diseases and development of new medical cannabis products and delivery methods. However, the medical cannabis market also faces certain challenges that could hinder its growth. Such factors include, regulatory uncertainty, lack of scientific evidence and negative public perception.

The COVID-19 pandemic has had a mixed impact on the medical cannabis market. It has led to increased demand for medical cannabis products due to increased stress and anxiety and increased access to medical cannabis. However, the pandemic has also had some negative impact on the medical cannabis market such as disruption of supply chains and businesses in the medical cannabis industry experiencing financial difficulties. Moreover, certain governments imposed stricter regulations on the medical cannabis industry during the pandemic.

Delvens Industry Expert’s Standpoint

The medical cannabis market is expected to grow during the forecast period. This growth can be attributed to various factors. Firstly, as of 2023, medical cannabis is legal in over 30 countries around the world, and this number is expected to grow in the coming years. This is due to the growing research that supports the use of medical cannabis for a variety of conditions, including chronic pain, nausea, seizures and anxiety. Moreover, the medical cannabis industry ins rapidly evolving, and new products and delivery methods are being developed all the time. This is making medical cannabis more accessible and convenient for patients, and it is also opening up new treatment possibilities. However, certain factors might hamper the growth of the market during the forecast period. The demand for medical cannabis is growing faster than the supply, which could lead to shortages in the future. This could drive up prices and make medicinal cannabis less accessible to patients. Moreover, synthetic alternatives to medical cannabis are being developed, and these could pose a threat to the industry.

Make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/medical-cannabis-market-trends-forecast-till-2030

Key Findings

Based on product, the market is segmented into oil, medical cannabis capsules, patch, whole flower, ground flower, vape pen, dried medical cannabis, creams & moisturizer, masks & serum, cleanser, and others. The flowers dominated the market in this segment. This is owing to the higher availability and huge consumer base for flower-based marijuana.

Based on derivatives, the market is bifurcated into Cannabidiol (CBD), Tetrahydrocannabinol (THC)/ Delta-8-Tetrahydrocannabinol, Cannabigerol (CBG), Cannabichromene (CBC), Cannabinol (CBN), Cannabicyclol (CBL), Others. The cannabidiol (CBD) dominated the market in this segment. This is due to wide range of application of cannabidiol in medical conditions such as seizure disorder or epilepsy, anxiety, pain, muscle disorder, Crohn’s disease, and Parkinson’s.

Based on route of administration, the market is segmented into oral solutions and capsules, inhalation (smoking, vaporizers), topicals, others. Inhalation dominated the market in this segment. Inhalation offers immediate effect and is the most widely used and effective method of consumption.

The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America, recreational legalization of marijuana began in 2012 in the US. As of 2022, various states, two territories and the district of Columbia have legalized it for recreational purposes.

Regional Analysis

North America to Dominate the Market

North America is estimated to account for the largest market share during the forecast period due to the increasing investment in medical cannabis.

Moreover, the legalization of cannabis in various countries in North America allows the region to dominate the market during the forecast period.

Competitive Landscape

Aurora Cannabis

BARNEY’S FARM

CANNABIS SEEDS USA

CANOPY GROWTH CORPORATION

Cresco Labs

EcoGen Biosciences

Elixinol Global Limited

ENDOCA

Extractas

FOLIUM BIOSCIENCES

HEXO Corp. (Zenabis Global Ltd)

HUMBOLDT SEED COMPANY

JAZZ Pharmaceuticals Inc. (GW Pharmaceuticals plc)

Medical Marijuana, Inc.

MediPharm Labs Inc.

Peace Naturals Project Inc.

PharmaHemp

Seed Cellar

Seeds For Me

Tilray

World Class Cannabis Seeds (Crop King Seeds)

Recent Developments

In August 2023, White Earth Nation Launches Medical Cannabis Program & Adult-Use Cannabis Sales becoming one of the first dispensaries to legally sell Adult-Use marijuana in Minnesota.

In Feb 2023, BOHECO introduces India’s first line of clinically trialled medical cannabis products. The company plans to provide hemp-based wellness by introducing clinically tested and research backed medical cannabis products.

Reasons to Acquire

Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.

Gain authentic and granular data access for the Medical Cannabis Market to understand the trends and the factors involved in changing market situations.

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Purchase This Report: https://www.delvens.com/checkout/medical-cannabis-market-trends-forecast-till-2030

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

[email protected]

#Medical Cannabis Market #Medical Cannabis #Medical Cannabis Market Size #Medical Cannabis Market Share #Medical Cannabis Market Trends

0 notes

delvenservices · 1 year ago

Text

Medical Cannabis Market Global Sales & Industry Share Analysis

Market Overview

The Medical Cannabis market size was estimated at USD 16.85 billion in 2023 and is projected to reach USD 68.26 billion in 2030 at a CAGR of 22.12% during the forecast period 2023-2030.

Request for the Sample pages: https://www.delvens.com/get-free-sample/medical-cannabis-market-trends-forecast-till-2030

Delvens Industry Expert's Standpoint

Key Findings

Make an Inquiry for the Research report: https://www.delvens.com/get-free-sample/medical-cannabis-market-trends-forecast-till-2030

Regional Analysis

North America to Dominate the Market

North America is estimated to account for the largest market share during the forecast period due to the increasing investment in medical cannabis.

Moreover, the legalization of cannabis in various countries in North America allows the region to dominate the market during the forecast period.

Competitive Landscape

Aurora Cannabis

BARNEY'S FARM

CANNABIS SEEDS USA

CANOPY GROWTH CORPORATION

Cresco Labs

EcoGen Biosciences

Elixinol Global Limited

ENDOCA

Extractas

FOLIUM BIOSCIENCES

HEXO Corp. (Zenabis Global Ltd)

HUMBOLDT SEED COMPANY

JAZZ Pharmaceuticals Inc. (GW Pharmaceuticals plc)

Medical Marijuana, Inc.

MediPharm Labs Inc.

Peace Naturals Project Inc.

PharmaHemp

Seed Cellar

Seeds For Me

Tilray

World Class Cannabis Seeds (Crop King Seeds)

Recent Developments

In August 2023, White Earth Nation Launches Medical Cannabis Program & Adult-Use Cannabis Sales becoming one of the first dispensaries to legally sell Adult-Use marijuana in Minnesota.

Purchase the Trending Report Now: https://www.delvens.com/checkout/medical-cannabis-market-trends-forecast-till-2030

Reasons to Acquire

Gain authentic and granular data access for the Medical Cannabis Market to understand the trends and the factors involved in changing market situations.

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope

The Medical Cannabis Market is segmented into various segments such as product, source, species, derivatives, application, route of administration, treatment type, distribution channel and region:

Based on Product

Oil

Dried Medical Cannabis

Medical Cannabis Capsules

Vape Pen

Whole Flower

Creams & Moisturizer

Ground Flower

Patch

Masks & Serum

Cleanser

Others

Based on Source

Synthetic

Natural

Based on Species

Cannabis Indica

Sativa

Hybrid

Based on Derivatives

Cannabidiol (CBD)

Tetrahydrocannabinol (THC)/ Delta-8-Tetrahydrocannabinol

Cannabigerol (CBG)

Cannabichromene (CBC)

Cannabinol (CBN)

Cannabicyclol (CBL)

Others

Based on Application

Pain Management

Anxiety

Muscle Spasm

Nausea

Appetite Loss

Eating Disorders

Inflammatory Bowel Diseases

Cancer

Arthritis

Wasting Syndrome (Cachexia)

Alzheimer's Disease

Epilepsy

Depression and Sleep Disorder

Multiple Sclerosis

Autism

Mental Health Conditions

Elevate Mood

Others

Based on Route of Administration

Oral Solutions and Capsules

Smoking

Vaporizers

Topicals

Others

Based on Treatment Type

Analgesic

Psychedelic

Antiviral

Aphrodisiac

Expectorant

Others

Based on Distribution Channel

B2B

B2C

About Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

[email protected]

0 notes

versatile-blogger-1 · 1 year ago

Text

Microbiome Marvels: Navigating The Emerging Landscape Of The Human Microbiome Market

Market Overview

The market refers to the collection of microorganisms, such as bacteria, viruses, and fungi,that live on and inside the human body. These microorganisms play a crucial role in maintaining human health and have been linked to various diseases and disorders. The market offers various products and therapies aimed at modulating the human microbiome to improve health outcomes.

Market Dynamics

The growing prevalence of chronic diseases is a major driver for the market. Increasing evidence suggests that imbalances in the microbiome can contribute to the development and progression of conditions such as obesity, diabetes, inflammatory bowel disease, and mental health disorders. The global Human Microbiome Market is estimated to be valued at US$91,075.4 billion in 2021 and is expected to exhibit a CAGR of 18.9% over the forecast period 2021-2028. As a result, there is a rising demand for microbiome-based therapeutics and diagnostics for the prevention and treatment of these diseases.

Furthermore, the increasing investment in research and development activities related to the human microbiome is expected to drive market growth. Several pharmaceutical and biotechnology companies are focusing on developing novel therapies targeting the microbiome, which opens up new opportunities for market players. For example, companies like Finch Therapeutics Group and Seres Therapeutics are developing microbiome-based drugs for the treatment of recurrent Clostridium difficile infection.

Market Key Trends

One key trend in the Human Microbiome Market is the growing interest in personalized medicine. Advancements in sequencing and bioinformatics technologies have enabled researchers to better understand the composition and functions of individual microbiomes. This knowledge can be used to develop personalized therapies tailored to an individual's unique microbiome profile. For example, Vedanta Biosciences is developing microbiome-based therapeutics for cancer patients, with the aim of improving response rates to immune checkpoint inhibitors.

SWOT Analysis

Strengths:

1. Growing awareness about the importance of the human microbiome in maintaining health.

2. Increasing investment in research and development activities related to the microbiome.

Weaknesses:

1. Limited understanding of the complex interactions between the microbiome and human health.

2. Challenges in developing standardized approaches for modulating the microbiome.

Opportunities:

1. Expansion of the Human Microbiome Market into new therapeutic areas, such as mental health and dermatology.

2. Collaboration between academia, industry, and government to accelerate microbiome research.

Threats:

1. Regulatory challenges in approving microbiome-based therapies.

2. Competition from alternative therapies and treatments.

Key Takeaways

The global Human Microbiome Market is expected to witness high growth, exhibiting a CAGR of 18.9% over the forecast period. This growth is driven by the increasing prevalence of chronic diseases and the growing investment in microbiome research and development. Personalized medicine is a key trend in the market, with the potential to revolutionize healthcare by tailoring therapies to individuals' unique microbiome profiles.

In terms of regional analysis, North America is expected to dominate the market due to the presence of key players and a favorable regulatory environment. Europe and Asia Pacific are also anticipated to witness significant growth, driven by increasing investments in healthcare infrastructure and rising awareness about the role of the microbiome in health.

Key players operating in the global Human Microbiome Market include Finch Therapeutics Group, Inc., Assembly Biosciences, Inc., Seres Therapeutics, Inc., Rebiotix Inc., Vedanta Biosciences, Inc., AOBiome, Immuron Ltd., OxThera AB, Osel Inc., SECOND GENOME THERAPEUTICS, ViThera Pharmaceuticals Inc., YSOPIA Bioscience, Gnubiotics Sciences, 4D Pharma Plc., Ferring Pharmaceuticals, Evelo Biosciences Inc., IGEN BIOLAB GROUP, Embion Technologies S.A, and ENTEROME SA. These companies are actively involved in research and development activities to develop innovative microbiome-based therapies and diagnostics.

#Human Microbiome Market #Human Microbiome Market Demand #Human Microbiome Market Trends #Human Microbiome Market Growth #Human Microbiome Market Analysis #Human Microbiome Market Sale #Coherent Market Insights

0 notes

healthcaremarketfmi · 1 year ago

Text

Chloangiocarcinoma (CCA) Therapeutics Market Size 2022 Growth Share, Industry Dynamics, Top Trends and Regional Analysis Forecast to 2033

The global Chloangiocarcinoma Therapeutics Market is anticipated to reach a market value of US$ 800 Million in 2023 and US$ 975.20 Million by registering a CAGR of 2% from 2023 to 2033. Inflammatory bowel disease, exposure to specific toxins, and changes in bile duct anatomy are all factors contributing to the growth of the cholangiocarcinoma therapeutics market. In the historical period from 2018 to 2022, the market for Chloangiocarcinoma therapeutics registered a CAGR of 1%.

During the forecast period 2023-2033, the Chloangiocarcinoma (CCA) Therapeutics market is expected to grow at a value of 2% CAGR, according to Future Market Insights. By the year 2033, the global market for Chloangiocarcinoma (CCA) Therapeutics is expected to rise up to a market valuation of US$ 975.20 Million. Growth of the market can be attributed to the rarity of diseases which in turn is increasing the scope for research and development of Chloangiocarcinoma (CCA) Therapeutics.

The use of precision medicine, which is a personalized approach to treatment that takes into account the patient’s genetic makeup and the specific characteristics of their cancer, is also being evaluated as a potential approach to treating CCA. In addition, researchers are also working to develop drugs that help the immune system fight cancer cells. This approach has shown promise in the treatment of other types of cancer and is being evaluated in clinical trials for CCA.

Furthermore, increasing cases of Chloangiocarcinoma in United States, China, India and Japan is creating lucrative opportunities for therapeutics of Chloangiocarcinoma. Efforts for developing innovate medication along with improved healthcare infrastructure in developed and developing regions the globe is shaping the landscape for Chloangiocarcinoma (CCA) therapeutics market.

Key Takeaways from the Market Study

The Chloangiocarcinoma (CCA) Therapeutics market is expected to grow at a value of 2% CAGR in the forecast period 2023 to 2033

By distribution channel, retail pharmacies expected to hold 40% of the market share in 2023 for Chloangiocarcinoma (CCA) Therapeutics market.

North America is expected to possess 40% market share for cholangiocarcinoma therapeutics market in 2023.

Asia Pacific is expected to hold 35% market share for Chloangiocarcinoma (CCA) therapeutics market in 2023.

“Increasing research and development activities for innovating medications and therapies for treating Chloangiocarcinoma (CCA) Therapeutics market.” states an FMI analyst

Competitive Landscape

Key players in the Chloangiocarcinoma therapeutics market are AstraZeneca, Decalth Systems, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals and Servier Pharmaceuticals

AstraZeneca, a key player in the Chloangiocarcinoma (CCA) therapeutics market is focusing on undertaking extensive research and development for innovating medications to reduce the intensity of the pain caused by the ailment.

Taiho Oncology, another key player in the Chloangiocarcinoma (CCA) therapeutics market is planning to integrate technology to maximize the benefit of immunotherapy.

For More Information: https://www.futuremarketinsights.com/reports/chloangiocarcinoma-therapeutics-market

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Chloangiocarcinoma (CCA) therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of treatment type (Chemotherapy, Targeted Therapy, Immunotherapy), distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa).

Key Segments Profiled in the Chloangiocarcinoma (CCA) Therapeutics Survey

Treatment Type:

Chemotherapy

Gemcitabine

Cisplatin

Oxaliplatin

Capecitabine

5 fluorouracil (5-FU)

Targeted Therapy

Pemigatinib

Infigratinib (Phase 3)

Ivosidenib (Phase 3)

Immunotherapy

Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

0 notes

businessindustry · 4 months ago

Text

Primary Sclerosing Cholangitis Market Size, Share and Future News by 2032

The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Primary Sclerosing Cholangitis Market?

The global primary sclerosing cholangitis market was valued at US$ 162.3 Million in 2023 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 319.1 Mn in 2032.

What are Primary Sclerosing Cholangitis?

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389

What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?

What is included in market segmentation?

The report has segmented the market into the following categories:

By Type

Classic PSC

Variant PSC

PSC Associated with Autoimmune Hepatitis

PSC with Cholangiocarcinoma

By Treatment Type

Ursodeoxycholic Acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Route of Administration

Oral

Parental

Others

By End-User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Acorda Therapeutics, Inc.

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Falk Pharma GmbH

Allergan Plc.

Shire Plc.

Durect Corporation

Conatus Pharmaceuticals, Inc.

Sirnaomics, Inc.

Shenzhen HighTide Biopharmaceutical Ltd.

Cymabay Therapeutics

Pliant Therapeutics

Immunic AG

View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

#Primary Sclerosing Cholangitis Market share #Primary Sclerosing Cholangitis Market size #Primary Sclerosing Cholangitis Market trends

0 notes

organicbusinessconsulting · 9 months ago

Text

Asia Endoscopy Medical Device Market Size, Trends, Growth & Demand 2032

Asia Endoscopy Medical Device Market Size Overview

The Asia Endoscopy Medical Device Market is estimated to reach USD XX billion by 2032 with a CAGR of XX%.

Exploring the Growth Drivers of the Asia Endoscopy Medical Device Industry

Moreover, the increasing awareness among patients and healthcare professionals about the benefits of minimally invasive procedures is fueling the adoption of endoscopy in the region. Compared

What challenges does the Asia Endoscopy Medical Device Market face?

In what ways has the COVID-19 pandemic affected Asia Endoscopy Medical Device Market?

The Asia Endoscopy Medical Device market is undergoing a transformative phase, marked by unprecedented growth, technological advancements, and a paradigm shift in healthcare practices. This blog post aims to dissect the current state of the market, shedding light on its size, growth trajectory, and the prevailing trends shaping the landscape across the Asian continent.

Market Size and Growth: The Asia Endoscopy Medical Device market has witnessed remarkable expansion in recent years, driven by factors such as increasing healthcare investments, rising awareness about minimally invasive procedures, and the burgeoning burden of gastrointestinal diseases. As of [current year], the market size stands at [provide data], underscoring the region’s pivotal role in the global endoscopy device landscape.

The growth of this market is attributed to the escalating demand for advanced medical technologies, coupled with a surge in healthcare infrastructure development across Asia. Countries like China, Japan, and India have emerged as key contributors to the expansion, reflecting a significant increase in endoscopic procedures and the adoption of innovative medical devices.

Download Free Sample Report

Trends Shaping the Market:

Rapid Technological Advancements: The Asia Endoscopy Medical Device market is at the forefront of technological innovations. Advancements in imaging technologies, robotics, and the integration of artificial intelligence (AI) are enhancing the precision and diagnostic capabilities of endoscopic devices.

Prevalence of Minimally Invasive Procedures: The preference for minimally invasive surgeries has risen substantially across Asia. Endoscopic procedures, with their reduced recovery times and lower risks, have become the cornerstone of modern medical practices. This trend is driving the adoption of endoscopy medical devices in various specialties, including gastroenterology, pulmonology, and gynecology.

Increasing Geriatric Population: The aging demographic in Asia has led to a surge in age-related diseases and conditions that necessitate diagnostic and therapeutic interventions. Endoscopy medical devices play a crucial role in addressing the healthcare needs of the elderly population, contributing to the market’s growth.

Growing Awareness and Accessibility: Rising awareness among healthcare professionals and patients alike about the benefits of endoscopic procedures has fueled the market. Moreover, increased accessibility to healthcare facilities and advancements in medical education have played a pivotal role in expanding the adoption of endoscopy medical devices.

Strategic Collaborations and Partnerships: Key players in the market are actively engaging in strategic collaborations and partnerships to strengthen their market presence. These collaborations facilitate the development of innovative technologies and help companies expand their product portfolios to cater to a diverse range of medical specialties.

Key Target Audience

Medical Device Manufacturers

Hospitals and Clinics

Healthcare Professionals (Surgeons, Physicians)

Distributors and Suppliers

Regulatory Authorities and Compliance Agencies

Research and Development Institutions

Asia Endoscopy Medical Device Market Segmentation

1. Product Type

Endoscopes

Visualization Systems

Endoscopic Ultrasound Systems

Endoscopic Accessories

2. Application

Gastrointestinal Endoscopy

Laparoscopy

Bronchoscopy

Arthroscopy

Urology Endoscopy

Gynecology Endoscopy

Others

3. End User

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Specialty Clinics

Others

4. Price Range

Premium-Priced Devices

Mid-Priced Devices

Economy-Priced Devices

5. By Country

China

Japan

India

South Korea

Australia

Mob : +91 9319642100

Noida One Tower Sec 62 Noida 201301

Sales : [email protected]

Website : https://www.organicmarketresearch.com

#consulting firm #market research #healthcare #Endoscopy #medical devices

0 notes

researchinhealthcare · 3 years ago

Text

Desmoid Tumors Market Research Report By 2023 | Global Industry Analysis, New Device Developments, Cost Estimation, Regional Overview

Desmoid Tumors Market Highlights :

Desmoid tumors are the benign fibrous growths which usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. According to the U.S National Library of Medicine, Desmoid tumors are very rare as the rate of occurrence is estimated to be 1 to 2 per 500,000 people worldwide.

It is also stated that nearly 900 to 1,500 new cases are registered per year in the United States. Tumors associated with familial adenomatous polyposis (FAP) are less common than sporadic desmoid tumors. On the molecular level, desmoid tumor is characterized by one of the two mutations in the gene i.e. mutations in the adenomatous polyposis coli (APC) gene, or in the β-catenin gene, CTNNB1. During diagnostic procedures CTNNB1 mutation is detected, especially, when pathological differential diagnosis is difficult.

The symptoms of desmoid tumors include a painless swelling or lump, pain and obstruction of the bowels, limping, pain caused by compressed nerves or muscles, and others. For the diagnosis of desmoid tumor there are many non-invasive methods available to detect desmoid tumor which include ultrasound, MRI scan, and CT scan. The actual diagnosis of this tumor can be made only after examining a small piece of the tumor by a trained pathologist.

Rising demand of effective chemotherapeutic agents, high unmet needs of current treatment, and increase in research and development expenditure will promote the growth of desmoid tumors market. According to the Desmoid Rare Foundation, individuals within the age group of 15 and 60 are more likely to get affected. It is also stated that the condition is more prevalent in women than in men (2:1).

High cost of treatment & management of desmoid tumors and related disorders, and lack of infrastructure in middle and low income countries may hamper the growth of the market.

It is estimated that desmoid tumors market is expected to grow at a CAGR 4.5% during the forecast period of 2017-2023.

Desmoid Tumors Market Regional Analysis :

The Americas dominate the desmoid tumors market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States. Furthermore, increasing participation of bigger players and new marketers towards advancement in treatment approaches have also attracted a great deal of attention.

Europe holds the second position in the desmoid tumors market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.

Asia Pacific is the fastest growing desmoid tumors market owing to the huge patient pool and developing healthcare technology.

The Middle East & Africa has the lowest market for desmoid tumors market due to lack of technical knowledge and poor medical facilities.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/4859

Desmoid Tumors Market Segmentation :

The desmoid tumors market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, market is segmented into biopsy, electron microscopic examination, immunohistochemical analysis, others

On the basis of treatment, market is classified into surgery, radiation therapy, anti-inflammatory medication, hormone therapy, chemotherapy, novel molecular-targeted therapy, others. Novel molecular-targeted therapy is further segmented into gleevec based therapy, and sorafenib based therapy

On the basis of end-user, market is segmented into hospital, clinics, and others.

Desmoid Tumors Market Key Players :

Some of key the players in the market are Amgen Inc., Novartis AG, Abbott Laboratories, Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm Group, F. Hoffmann-La Roche Ltd, and others.

Browse Full Report @ https://www.marketresearchfuture.com/reports/desmoid-tumors-market-4859

#Desmoid Tumors Market Research Report #Desmoid Tumors Market Analysis #Desmoid Tumors Market Research Analysis #Desmoid Tumors Market Trends

1 note · View note